Skip to main content
. 2019 Jan 23;46(3):186–192. doi: 10.1111/1346-8138.14761

Figure 2.

Figure 2

Percentage of patients with PASI response from week 52 through week 152 in secukinumab 300 mg arm. The data was analyzed using observed values without imputation of any missing values. FI, fixed interval; PASI, Psoriasis Area and Severity Index; RAN, retreatment as needed.